New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2013
06:06 EDTCTICCell Therapeutics announces positive results from OPAL study of tosedostat
Cell Therapeutics and Chroma Therapeutics announced that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia. Tosedostat is an oral aminopeptidase inhibitor which has been shown to deprive tumor cells of the amino acid building blocks they need to make proteins necessary for tumor cell survival. The trial showed that once-daily oral tosedostat resulted in a disease control rate of 51%. Subset analyses suggested the greatest benefit occurred in the difficult-to-treat patients with prior myelodysplastic syndrome or those that had received prior hypomethylating therapy. Adverse events were mild, predictable and manageable.
News For CTIC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 29, 2014
16:18 EDTCTICCTI BioPharma raises FY14 operating loss view to $66M-$71M from $45M-$50M
As a result of the stock issuance in the transaction described above with Chroma resulting in an expense recognition of approximately $21M, CTI has revised its financial guidance such that non-GAAP operating loss for 2014 is now expected to range from approximately $66M-$71M rather than $45M-$50M as previously expected, which excludes non-cash share-based compensation expense.
16:16 EDTCTICCTI BioPharma reports Q3 EPS 3c, consensus (3c)
Reports Q3 revenue $39.53M, consensus $24.3M.
October 27, 2014
05:14 EDTCTICCTI BioPharma acquires exclusive worldwide license to tosedostat
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use